These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 16033264)

  • 1. Combination of molecular modeling, site-directed mutagenesis, and SAR studies to delineate the binding site of pyridopyrimidine antagonists on the human CCK1 receptor.
    Martín-Martínez M; Marty A; Jourdan M; Escrieut C; Archer E; González-Muñiz R; García-López MT; Maigret B; Herranz R; Fourmy D
    J Med Chem; 2005 Jul; 48(15):4842-50. PubMed ID: 16033264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectivity toward CCK2 receptors.
    Muñoz-Ruiz P; García-López MT; Cenarruzabeitia E; Del Río J; Dufresne M; Foucaud M; Fourmy D; Herranz R
    J Med Chem; 2004 Oct; 47(21):5318-29. PubMed ID: 15456276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the binding mode of thienopyrimidinedione antagonists to the human gonadotropin releasing hormone receptor using structure-activity relationships, site-directed mutagenesis, and homology modeling.
    Betz SF; Lio FM; Gao Y; Reinhart GJ; Guo Z; Mesleh MF; Zhu YF; Struthers RS
    J Med Chem; 2006 Oct; 49(21):6170-6. PubMed ID: 17034124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach.
    Berkhout TA; Blaney FE; Bridges AM; Cooper DG; Forbes IT; Gribble AD; Groot PH; Hardy A; Ife RJ; Kaur R; Moores KE; Shillito H; Willetts J; Witherington J
    J Med Chem; 2003 Sep; 46(19):4070-86. PubMed ID: 12954060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chapter 12. The use of receptor homology modeling to facilitate the design of selective chemokine receptor antagonists.
    Carter PH; Tebben AJ
    Methods Enzymol; 2009; 461():249-79. PubMed ID: 19480923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the binding pocket for pyridopyrimidine ligands at the CCK1 receptor by molecular docking.
    Toumi-Maouche A; Maouche B; Taïri-Kellou S; El-Aoufi S; Martín-Martínez M; González-Muñiz R; Fourmy D; Maigret B
    J Mol Model; 2008 Apr; 14(4):303-14. PubMed ID: 18286312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular interaction of a potent nonpeptide agonist with the chemokine receptor CCR8.
    Jensen PC; Nygaard R; Thiele S; Elder A; Zhu G; Kolbeck R; Ghosh S; Schwartz TW; Rosenkilde MM
    Mol Pharmacol; 2007 Aug; 72(2):327-40. PubMed ID: 17652183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process.
    Escrieut C; Gigoux V; Archer E; Verrier S; Maigret B; Behrendt R; Moroder L; Bignon E; Silvente-Poirot S; Pradayrol L; Fourmy D
    J Biol Chem; 2002 Mar; 277(9):7546-55. PubMed ID: 11724786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket.
    Castonguay LA; Weng Y; Adolfsen W; Di Salvo J; Kilburn R; Caldwell CG; Daugherty BL; Finke PE; Hale JJ; Lynch CL; Mills SG; MacCoss M; Springer MS; DeMartino JA
    Biochemistry; 2003 Feb; 42(6):1544-50. PubMed ID: 12578367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
    Escherich A; Lutz J; Escrieut C; Fourmy D; van Neuren AS; Müller G; Schafferhans A; Klebe G; Moroder L
    Biopolymers; 2000-2001; 56(2):55-76. PubMed ID: 11592053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models.
    Tafi A; Bernardini C; Botta M; Corelli F; Andreini M; Martinelli A; Ortore G; Baraldi PG; Fruttarolo F; Borea PA; Tuccinardi T
    J Med Chem; 2006 Jul; 49(14):4085-97. PubMed ID: 16821770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor.
    Betz SF; Reinhart GJ; Lio FM; Chen C; Struthers RS
    J Med Chem; 2006 Jan; 49(2):637-47. PubMed ID: 16420049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor model.
    Tuccinardi T; Schenone S; Bondavalli F; Brullo C; Bruno O; Mosti L; Zizzari AT; Tintori C; Manetti F; Ciampi O; Trincavelli ML; Martini C; Martinelli A; Botta M
    ChemMedChem; 2008 Jun; 3(6):898-913. PubMed ID: 18338422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: mapping of the receptor binding pocket by in silico docking studies.
    Di Fabio R; Arban R; Bernasconi G; Braggio S; Blaney FE; Capelli AM; Castiglioni E; Donati D; Fazzolari E; Ratti E; Feriani A; Contini S; Gentile G; Ghirlanda D; Sabbatini FM; Andreotti D; Spada S; Marchioro C; Worby A; St-Denis Y
    J Med Chem; 2008 Nov; 51(22):7273-86. PubMed ID: 18975927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationship of the first nonpeptidergic inverse agonists for the human cytomegalovirus encoded chemokine receptor US28.
    Hulshof JW; Casarosa P; Menge WM; Kuusisto LM; van der Goot H; Smit MJ; de Esch IJ; Leurs R
    J Med Chem; 2005 Oct; 48(20):6461-71. PubMed ID: 16190772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
    Colotta V; Lenzi O; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Traini C; Pedata F; Morizzo E; Moro S
    J Med Chem; 2009 Apr; 52(8):2407-19. PubMed ID: 19301821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor.
    Macion-Dazard R; Callahan N; Xu Z; Wu N; Thibonnier M; Shoham M
    J Pharmacol Exp Ther; 2006 Feb; 316(2):564-71. PubMed ID: 16234409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of overlapping but differential binding sites for the high-affinity CXCR3 antagonists NBI-74330 and VUF11211.
    Scholten DJ; Roumen L; Wijtmans M; Verkade-Vreeker MC; Custers H; Lai M; de Hooge D; Canals M; de Esch IJ; Smit MJ; de Graaf C; Leurs R
    Mol Pharmacol; 2014 Jan; 85(1):116-26. PubMed ID: 24174496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temperature-dependent variations of ligand-receptor contact points in hAT(1).
    Arsenault J; Renaud MP; Clément M; Fillion D; Guillemette G; Leduc R; Lavigne P; Escher E
    J Pept Sci; 2007 Sep; 13(9):575-80. PubMed ID: 17600857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.